ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

anbenitamab repodatecan

Its studies are mostly in Breast Neoplasms · Colorectal Neoplasms · Stomach Neoplasms · Ovarian Neoplasms, led by 2 companies.

Drug pageAnbenitamab repodatecan: every studyAll 9 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Sep 22, 20238 company-led studies, 7 open or runningLicense: Alphamab → CSPC (JMT-Bio), Sep 2024Next primary completion: Dec 30, 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Alphamab Oncology43 open or runningphase 3since Sep 22, 2023Aug 4, 2022Dec 30, 2026phase 3 · NCT06751485
CSPC Pharmaceutical Groupits history only44 open or runningphase 3since Jan 6, 2025Jan 6, 2025May 29, 2027phase 2 · NCT07545044
  • Named in CSPC Pharmaceutical Group’s own pipeline as anbenitamab repodatecan (JSKN003), phase 3, as of Aug 20, 2026 (source).

How these companies relate

From the companies’ own releases and filings, each linked; the registry does not say.

History and studies of Alphamab Oncology only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). A diamond marks a license, acquisition or co-development, from the companies’ own releases and filings. An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Aug 4, 2022First study: phase 1 study in Advanced Solid TumorsFirst studyNCT05494918 · 62 enrolled · Australia
  2. Jan 10, 2023Phase 2 study in Advanced Solid TumorNCT05744427 · 725 enrolled · China
  3. Sep 22, 2023Phase 3 study in Breast NeoplasmsNCT06079983 · 400 planned · China
  4. Sep 30, 2024CSPC (JMT-Bio) licensed it from AlphamabLicenseMainland China, in cancer · announced · Alphamab Oncology (release)
  5. Dec 25, 2024Phase 3 study in Ovarian NeoplasmsNCT06751485 · 430 planned
  6. Feb 13, 2025Named anbenitamab repodatecanINNProposed as its International Nonproprietary Name in WHO's List 132 · before, JSKN003

Ahead

  1. Dec 30, 2026Primary completion: phase 3 study in Ovarian NeoplasmsNCT06751485

TargetBeta

“An antibody-drug conjugate (ADC) composed of the bispecific monoclonal antibody anbenitamab, directed against two distinct epitopes of the extracellular dimerization domain of the tumor-associated antigen (TAA) human tyrosine kinase receptor epidermal growth factor receptor 2 (HER2; ErbB2; HER-2)…”NCIt, read by Claude
“An antibody-drug conjugate (ADC) composed of the bispecific monoclonal antibody anbenitamab, directed against two distinct epitopes of the extracellular dimerization domain of the tumor-associated antigen (TAA) human tyrosine kinase receptor epidermal growth factor receptor 2 (HER2; ErbB2; HER-2), s”NCIt, by rule

Other programs on ERBB2

ProgramCompanyFurthest phaseStudies
TrastuzumabruleHoffmann-La Rochephase 485
pertuzumabruleHoffmann-La Rochephase 456
trastuzumab deruxtecanruleDaiichi Sankyophase 449
tucatinibrulePfizerphase 425
disitamab vedotinRemeGenphase 336
trastuzumab rezetecanruleJiangsu HengRui Medicinephase 336
Lutetium-177Novartisphase 324
trastuzumab brengitecanSichuan Biokin Pharmaceuticalphase 321
Gallium-68Philogenphase 317
zongertinibruleBoehringer Ingelheimphase 315
Anti-HER2/Topoisomerase I Inhibitor ADC TQB2102Sino Biopharmaceuticalphase 313
sunvozertinibruleDizal Pharmaceuticalsphase 312

Studies

All 4 Alphamab Oncology leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06751485Ovarian Neoplasms3Not yet recruitingDec 30, 2026430
NCT06079983Breast Neoplasms · China3RecruitingApr 1, 2026400
NCT05744427Advanced Solid Tumor · China2Active, not recruitingJul 30, 2026725
NCT05494918Advanced Solid Tumors · Australia1CompletedApr 15, 202562

How it is read

Names in the registry

  • “JSKN003”, 8 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.